C12Q2521/327

METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS
20220331399 · 2022-10-20 · ·

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION
20220333185 · 2022-10-20 ·

The disclosure provides for methods, compositions, systems, devices, and kits for whole transcriptome amplification using stochastic barcodes.

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION
20220333185 · 2022-10-20 ·

The disclosure provides for methods, compositions, systems, devices, and kits for whole transcriptome amplification using stochastic barcodes.

Detection of target nucleic acid sequence on solid phase by PTO cleavage and extension using HCTO assay
11447814 · 2022-09-20 · ·

The present invention relates to the detection of a target nucleic acid sequence from a DNA or a mixture of nucleic acids by a PCE-hCTO (PTO Cleavage and Extension using hCTO) assay on a solid phase. According to the present invention, the extended duplex is formed in a liquid phase in a target-dependent manner and then its presence is detected on a solid phase. Since hCTO is not immobilized onto a solid phase, the extended duplex is more effectively formed in a liquid phase.

Detection of target nucleic acid sequence on solid phase by PTO cleavage and extension using HCTO assay
11447814 · 2022-09-20 · ·

The present invention relates to the detection of a target nucleic acid sequence from a DNA or a mixture of nucleic acids by a PCE-hCTO (PTO Cleavage and Extension using hCTO) assay on a solid phase. According to the present invention, the extended duplex is formed in a liquid phase in a target-dependent manner and then its presence is detected on a solid phase. Since hCTO is not immobilized onto a solid phase, the extended duplex is more effectively formed in a liquid phase.

MATERIALS AND METHODS FOR SERIAL MULTIPLEXED DETECTION OF RNA IN CELLS AND TISSUES
20220298563 · 2022-09-22 ·

This disclosure describes materials and methods for effectively performing serial multiplexed FISH analysis.

MATERIALS AND METHODS FOR SERIAL MULTIPLEXED DETECTION OF RNA IN CELLS AND TISSUES
20220298563 · 2022-09-22 ·

This disclosure describes materials and methods for effectively performing serial multiplexed FISH analysis.

RNA AFFINITY PURIFICATION
20220290125 · 2022-09-15 · ·

Provided herein, in some embodiments, are methods of purifying a nucleic acid preparation. The methods may comprise contacting a nucleic acid preparation comprising messenger ribonucleic acid with an RNase III enzyme that is immobilized on a solid support and binds to double-stranded RNA contaminants.

RNA AFFINITY PURIFICATION
20220290125 · 2022-09-15 · ·

Provided herein, in some embodiments, are methods of purifying a nucleic acid preparation. The methods may comprise contacting a nucleic acid preparation comprising messenger ribonucleic acid with an RNase III enzyme that is immobilized on a solid support and binds to double-stranded RNA contaminants.

COMBINATORIAL DNA SCREENING

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.